News

B-cell cloning represents a pivotal expansion of the company’s MPS Discovery Engine® platform for isolating monoclonal antibodies against membrane protein targets. Combined with the company’s proprietary Lipoparticle technology

SYM-1219 is a potent, next-generation 5-nitroimidazole antibiotic intended for single-dose oral treatment of BV. Symbiomix also announced a successful meeting with the US Food & Drug Administration (FDA)

Afstyla, which is anticipated to be available in the US early this US summer, is indicated for routine prophylaxis to avoid or reduce the frequency of bleeding episodes;

Gazyva/Gazyvaro is an engineered monoclonal antibody designed to attach to CD20, a protein found on several B cells, but not on stem cells or plasma cells. It is

Fast Track designation is granted to facilitate and expedite development and review for drugs that are intended to treat a serious condition and with nonclinical or clinical data

Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). The Phase 3 trial is expected to enroll approximately 322 patients with recurrent or

Myriam Delvaux, global pharmaceutical marketing leader for Dow Corning Healthcare will lead the webinar and explain how silicone-based ingredients and excipients can help generate innovative product forms with

The company acquired six OTC brands from Ducere Pharma, including DOAN’S, BUFFERIN, NUPERCAINAL Ointment, CRUEX Nail Gel, COMTREX, and MYOFLEX. "These legacy products enjoy strong brand equity built

Arrivo was founded by Steve Butts, Bill Wofford, Dr. Michael Ackermann and Dr. Jed Black, and located in North Carolina’s Research Triangle Park region. Mr. Butts and Mr.